In this sense, Voron and colleagues demonstrated that VEGF-A increases the percentages of TIM-3+-expressing CD8+ T cells and highlighted the role of VEGF-A in resistance to anti-PD-1 treatment in a murine model of colorectal cancer (26). The gene discussed is CD8A; the disease is colorectal cancer.